דף הבית

Nyxoah מדווחת על תוצאות כספיות ותפעוליות לרבעון הראשון

פרסום המאמר באתרך

באפשרותך לפרסם את המאמר הזה באתרך בכפוף לתנאי השימוש .בפרסום המאמר עליך להקפיד על הכללים הבאים: יש לפרסם את כותרת המאמר, תוכנו, וכן פרטים אודות כותב המאמר. כמו כן יש לכלול קישור לאתר מאמרים עסקיים ומקצועיים (http://www.portal-asakim.com).

בחזרה למאמר

כותרת המאמר:


תקציר המאמר:
החברה בדרך לאישור PMA צפוי ברבעון השני של 2025 דרישות האימות של ה-FDA הושלמו בהצלחה, בדיקת האתר הסופית בעיצומה

מילות מפתח:


קישור ישיר למאמר:


גירסת HTML:
<html> <head> <title>Nyxoah מדווחת על תוצאות כספיות ותפעוליות לרבעון הראשון</title> <meta name="description" content="החברה בדרך לאישור PMA צפוי ברבעון השני של 2025 דרישות האימות של ה-FDA הושלמו בהצלחה, בדיקת האתר הסופית בעיצומה"> <meta name="keywords" content="GLOBE NEWSWIRE, noy tikshoret"> <meta name="expires" CONTENT="never"> <meta name="language" CONTENT="hebrew"> <meta name="distribution" CONTENT="Global"> <meta name="robots" content="index, follow"> <meta http-equiv="Content-Type" content="text/html; charset=windows-1255"> </title> <body dir="rtl"> <h1>Nyxoah מדווחת על תוצאות כספיות ותפעוליות לרבעון הראשון</h1><br/> <br/><strong>נכתב על ידי: <a title="Nyxoah מדווחת על תוצאות כספיות ותפעוליות לרבעון הראשון" href="http://www.portal-asakim.com/Authors//Author576.aspx ">חיים נוי</a></strong><br/> <br/><p align="center">Nyxoah מדווחת על תוצאות כספיות ותפעוליות לרבעון הראשון</p> <p align="center"><em>החברה בדרך לאישור PMA צפוי ברבעון השני של 2025</em></p> <p align="center"><em>דרישות האימות של ה-FDA הושלמו בהצלחה, בדיקת האתר הסופית בעיצומה</em></p> <p>מונט-סנט-גיברט, בלגיה, 14 במאי 2025, (GLOBE NEWSWIRE) :</p> <p>Nyxoah SA (נאסד"ק/יורונקסט בריסל: NYXH) ("Nyxoah" או "החברה"), חברת טכנולוגיות רפואיות שמתמקדת בפיתוח ומסחור של פתרונות ושירותים חדשניים לדום נשימה בשינה (OSA) באמצעות נוירומודולציה, דיווחה היום על תוצאות כספיות ותפעוליות לרבעון הראשון של 2025.</p> <p align="right">REGULATED INFORMATION</p> <p align="center">Nyxoah Reports First Quarter Financial and Operating Results</p> <p align="center"><br /> <em>Company On Track for Anticipated PMA Approval in the Second Quarter of 2025</em><br /> <em>Successfully Completed FDA Validation Requirements, Final Site Inspection in Progress</em></p> <p>Mont-Saint-Guibert, Belgium – May 14, 2025, (GLOBE NEWSWIRE):</p> <p>Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the first quarter of 2025.</p> <p>Recent Financial and Operating Highlights</p> <ul type="disc"> <li>Receivedan FDA Approvable Letter indicating the FDA will approve the Company’s PMAapplication for its Genio® system subject to satisfactory completion of amanufacturing facilities, methods and controls review</li> <li>Successfullycompleted FDA validation requirements, final site inspection in progressat the U.S. contract manufacturing site</li> <li>Revenuefor the first quarter of 2025 was €1.1 million, compared to €1.2 million inthe first quarter of 2024</li> <li>LaunchedGenio® 2.1 patient software upgrade in international commercial markets</li> <li>Cash, cashequivalents and financial assets were €63.0 million at March 31, 2025,compared to €85.6 million at the end of 2024</li> </ul> <p>"We are excited that we are in the final stage of the FDA review process of our Genio® system in the United States," commented Olivier Taelman, Nyxoah's Chief Executive Officer. "The FDA Approvable Letter we received previously confirms that our application substantially meets the requirements of the Federal Food, Drug and Cosmetic Act, including biocompatibility and acceptance of our clinical data demonstrating the safety and effectiveness of the Genio® system. We have successfully completed the final process validation requested by the FDA. We understand that the last step toward FDA approval is an on-site inspection at the U.S. manufacturing site which we expect to be completed shortly. As part of the PMA process, this site has already successfully passed an on-site inspection with no deficiencies, which gives us confidence in completing this regulatory step. We continue to anticipate that our application could potentially be approved in the second quarter of 2025."</p> <p><em>Revenue</em></p> <p>Revenue was €1.1 million for the first quarter ending March 31, 2025, compared to €1.2 million for the first quarter ending March 31, 2024.</p> <p><em>Cost of Goods Sold</em></p> <p>Cost of goods sold was €406,000 for the first quarter ending March 31, 2025, representing a gross profit of €0.7 million, or gross margin of 61.8%. This compares to cost of goods sold of €455,000 in the first quarter ending March 31, 2024, for a gross profit of €0.8 million, or gross margin of 62.7%.</p> <p><em>Research and Development</em></p> <p>For the first quarter ending March 31, 2025, research and development expenses were €9.0 million, versus €7.2 million for the first quarter ending March 31, 2024. The increase in research and development expenses was primarily due to higher R&D activities and clinical study expenses.</p> <p><em>Selling, General and Administrative</em></p> <p>For the first quarter ending March 31, 2025, selling, general and administrative expenses were €12.4 million, versus €6.0 million for the first quarter ending March 31, 2024. The increase in selling, general and administrative expenses was primarily due to an increase in costs to support the commercialization of Genio® system, the Company’s overall scale-up preparations for the upcoming commercialization of Genio® system in the US upon receipt of FDA approval.</p> <p><em>Operating Loss</em></p> <p>Total operating loss for the first quarter ending March 31, 2025 was €20.6 million, versus €12.2 million in the first quarter 2024, respectively. This was driven by an increase in selling, general and administrative expenses to support commercialization of the Genio system, the Company’s overall scale-up preparations for the upcoming commercialization of Genio® system in the US upon receipt of FDA approval and increased R&D activities and clinical study expenses.</p> <p>Cash Position</p> <p>As of March 31, 2025, cash, cash equivalents and financial assets totaled €63.0 million, compared to €85.6 million at the end of 2024.</p> <p>First Quarter 2025</p> <p>Nyxoah’s financial report for the first quarter of 2025, including details of the consolidated results, are available on the investor page of Nyxoah’s website (<a href="https://www.globenewswire.com/Tracker?data=LAt8e26kreZ8KPTmzUyYSJ_eBmaymE2eVB1X46bPUbsLQYgEDyCdwdD9yUfjeA0sdXeEG6Eh5_sGym7-6nvCzqKGrIPBGmtwYSoJkYHXCEC3cwrrMsvGEQVBVndHIkDq4eF997U1IQJkZ4i2P2cn-Q==" target="_blank">https://investors.nyxoah.com/financials</a>).</p> <p>Progress Toward FDA PMA Approval</p> <p>On March 26, 2025, Nyxoah announced that the U.S. Food and Drug Administration (FDA) issued an Approvable Letter regarding the Company's Pre-Market Approval (PMA) application for the Genio® system. The Approvable Letter means that Nyxoah's application for marketing the device in the United States substantially meets the requirements of the Federal Food, Drug and Cosmetic Act and the FDA's PMA implementing regulations.</p> <p>The FDA has accepted all other data provided with the PMA submission, including most importantly that the clinical study demonstrates the safety and effectiveness of the Genio® system. Nyxoah has successfully completed the validation work requested by the FDA for the manufacturing process used for a component of the Genio system at the U.S. manufacturing site. The Company submitted the required documentation to the FDA, which has reviewed this validation work and confirmed they have no further questions. We believe that the last step before full PMA approval is an on-site FDA inspection of the U.S. manufacturing site which we expect to be completed shortly. As part of the PMA process, this site already passed an on-site inspection with no deficiencies, giving the Company confidence in completing this regulatory step. Nyxoah anticipates that its application could potentially be approved in the second quarter of 2025.</p> <p>Conference call and webcast presentation</p> <p>Company management will host a conference call to discuss financial results on Wednesday, May 14, 2025, beginning at 2:00pm CET / 8:00am ET.</p> <p>A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: <a href="https://www.globenewswire.com/Tracker?data=5nqDhP3wJJIwqW8izRnBdg_m1CWSLuYqe5W2K2NPcsxdrdselvTRG-VGOxIi3q4qVHIj324eJ38OBid5I-Pyh89PCBaY9owHzy2AmxKipvnVY34EGitWMv8iSET82g2ctYNNHr8VIuP4C7n0sOXpLA==" target="_blank">Nyxoah's Q1 2025 Earnings Call Webcast</a>. For those not planning to ask a question of management, the Company recommends listening via the webcast.</p> <p>If you plan to ask a question, please use the following link: <a href="https://www.globenewswire.com/Tracker?data=5nqDhP3wJJIwqW8izRnBdg_m1CWSLuYqe5W2K2NPcswqJvwmXHO_-3G5v9VzLxiUh1EyPBQqVYk3r44l0IlTpN6MzBoQ5G7oTSTsVEtkJJX6kvdC1nm5AbgLo4xJdhaD-x_rz-J0SeIwwdn23SypthQtLwwNR2qdSI4XOwId0cEkl3Ihub6Jn8eZHh9mlQCn" target="_blank">Nyxoah's Q1 2025 Earnings Call</a>. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.</p> <p>The archived webcast will be available for replay shortly after the close of the call.</p> <p>About Nyxoah</p> <p>Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.</p> <p>Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study.</p> <p>Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.</p> <p>Contacts:</p> <p>Nyxoah<br /> John Landry, CFO<br /> <a href="https://www.globenewswire.com/Tracker?data=nf81CUuCq8GPo430PDgNIxkgkPxVJ3BhpWKkGsFD8H8BudVb80vjd8nLykyuAC5s_1qT5vIXwd_auF6TeSy6QQ==" target="_blank">IR@nyxoah.com</a></p> <p>For Media<br /> In United States<br /> FINN Partners – Glenn Silver<br /> glenn.silver@finnpartners.com</p> <p>For Media<br /> Belgium/France<br /> Backstage Communication – Gunther De Backer<br /> gunther@backstagecom.be</p> <p>International/Germany<br /> MC Services – Anne Hennecke<br /> nyxoah@mc-services.eu</p> <p>Attachment</p> <ul type="disc"> <li>ENGLISH_Q1 2025 Earnings PR_V3</li> </ul> <p>*** הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית GlobeNewswire</p> <br/><br/> <strong><u>פרטים אודות כותב המאמר</u></strong> <br/> <p><strong>חיים נוי, עיתונאי, עורך ראשי של סוכנות החדשות הבינ"ל IPA, לשעבר עורך ראשי של סוכנות הידיעות עתים, חבר תא מבקרי התיאטרון באגודת העיתונאים</strong></p> <br/><a href="http://www.portal-asakim.com"> מקור המאמר: אתר מאמרים עסקיים ומקצועיים</a>

גירסת טקסט:
Nyxoah מדווחת על תוצאות כספיות ותפעוליות לרבעון הראשון Nyxoah מדווחת על תוצאות כספיות ותפעוליות לרבעון הראשון החברה בדרך לאישור PMA צפוי ברבעון השני של 2025 דרישות האימות של ה-FDA הושלמו בהצלחה, בדיקת האתר הסופית בעיצומה מונט-סנט-גיברט, בלגיה, 14 במאי 2025, (GLOBE NEWSWIRE) : Nyxoah SA (נאסד"ק/יורונקסט בריסל: NYXH) ("Nyxoah" או "החברה"), חברת טכנולוגיות רפואיות שמתמקדת בפיתוח ומסחור של פתרונות ושירותים חדשניים לדום נשימה בשינה (OSA) באמצעות נוירומודולציה, דיווחה היום על תוצאות כספיות ותפעוליות לרבעון הראשון של 2025. REGULATED INFORMATION Nyxoah Reports First Quarter Financial and Operating Results Company On Track for Anticipated PMA Approval in the Second Quarter of 2025 Successfully Completed FDA Validation Requirements, Final Site Inspection in Progress Mont-Saint-Guibert, Belgium – May 14, 2025, (GLOBE NEWSWIRE): Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the first quarter of 2025. Recent Financial and Operating Highlights Receivedan FDA Approvable Letter indicating the FDA will approve the Company’s PMAapplication for its Genio® system subject to satisfactory completion of amanufacturing facilities, methods and controls review Successfullycompleted FDA validation requirements, final site inspection in progressat the U.S. contract manufacturing site Revenuefor the first quarter of 2025 was €1.1 million, compared to €1.2 million inthe first quarter of 2024 LaunchedGenio® 2.1 patient software upgrade in international commercial markets Cash, cashequivalents and financial assets were €63.0 million at March 31, 2025,compared to €85.6 million at the end of 2024 "We are excited that we are in the final stage of the FDA review process of our Genio® system in the United States," commented Olivier Taelman, Nyxoah's Chief Executive Officer. "The FDA Approvable Letter we received previously confirms that our application substantially meets the requirements of the Federal Food, Drug and Cosmetic Act, including biocompatibility and acceptance of our clinical data demonstrating the safety and effectiveness of the Genio® system. We have successfully completed the final process validation requested by the FDA. We understand that the last step toward FDA approval is an on-site inspection at the U.S. manufacturing site which we expect to be completed shortly. As part of the PMA process, this site has already successfully passed an on-site inspection with no deficiencies, which gives us confidence in completing this regulatory step. We continue to anticipate that our application could potentially be approved in the second quarter of 2025." Revenue Revenue was €1.1 million for the first quarter ending March 31, 2025, compared to €1.2 million for the first quarter ending March 31, 2024. Cost of Goods Sold Cost of goods sold was €406,000 for the first quarter ending March 31, 2025, representing a gross profit of €0.7 million, or gross margin of 61.8%. This compares to cost of goods sold of €455,000 in the first quarter ending March 31, 2024, for a gross profit of €0.8 million, or gross margin of 62.7%. Research and Development For the first quarter ending March 31, 2025, research and development expenses were €9.0 million, versus €7.2 million for the first quarter ending March 31, 2024. The increase in research and development expenses was primarily due to higher R&D activities and clinical study expenses. Selling, General and Administrative For the first quarter ending March 31, 2025, selling, general and administrative expenses were €12.4 million, versus €6.0 million for the first quarter ending March 31, 2024. The increase in selling, general and administrative expenses was primarily due to an increase in costs to support the commercialization of Genio® system, the Company’s overall scale-up preparations for the upcoming commercialization of Genio® system in the US upon receipt of FDA approval. Operating Loss Total operating loss for the first quarter ending March 31, 2025 was €20.6 million, versus €12.2 million in the first quarter 2024, respectively. This was driven by an increase in selling, general and administrative expenses to support commercialization of the Genio system, the Company’s overall scale-up preparations for the upcoming commercialization of Genio® system in the US upon receipt of FDA approval and increased R&D activities and clinical study expenses. Cash Position As of March 31, 2025, cash, cash equivalents and financial assets totaled €63.0 million, compared to €85.6 million at the end of 2024. First Quarter 2025 Nyxoah’s financial report for the first quarter of 2025, including details of the consolidated results, are available on the investor page of Nyxoah’s website (https://investors.nyxoah.com/financials). Progress Toward FDA PMA Approval On March 26, 2025, Nyxoah announced that the U.S. Food and Drug Administration (FDA) issued an Approvable Letter regarding the Company's Pre-Market Approval (PMA) application for the Genio® system. The Approvable Letter means that Nyxoah's application for marketing the device in the United States substantially meets the requirements of the Federal Food, Drug and Cosmetic Act and the FDA's PMA implementing regulations. The FDA has accepted all other data provided with the PMA submission, including most importantly that the clinical study demonstrates the safety and effectiveness of the Genio® system. Nyxoah has successfully completed the validation work requested by the FDA for the manufacturing process used for a component of the Genio system at the U.S. manufacturing site. The Company submitted the required documentation to the FDA, which has reviewed this validation work and confirmed they have no further questions. We believe that the last step before full PMA approval is an on-site FDA inspection of the U.S. manufacturing site which we expect to be completed shortly. As part of the PMA process, this site already passed an on-site inspection with no deficiencies, giving the Company confidence in completing this regulatory step. Nyxoah anticipates that its application could potentially be approved in the second quarter of 2025. Conference call and webcast presentation Company management will host a conference call to discuss financial results on Wednesday, May 14, 2025, beginning at 2:00pm CET / 8:00am ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q1 2025 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the following link: Nyxoah's Q1 2025 Earnings Call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. The archived webcast will be available for replay shortly after the close of the call. About Nyxoah Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study. Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States. Contacts: Nyxoah John Landry, CFO IR@nyxoah.com For Media In United States FINN Partners – Glenn Silver glenn.silver@finnpartners.com For Media Belgium/France Backstage Communication – Gunther De Backer gunther@backstagecom.be International/Germany MC Services – Anne Hennecke nyxoah@mc-services.eu Attachment ENGLISH_Q1 2025 Earnings PR_V3 *** הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית GlobeNewswire נכתב על ידי חיים נוי, עיתונאי, עורך ראשי של סוכנות החדשות הבינ"ל IPA, לשעבר עורך ראשי של סוכנות הידיעות עתים, חבר תא מבקרי התיאטרון באגודת העיתונאים מקור המאמר:אתר מאמרים עסקיים ומקצועיים http://www.portal-asakim.com
בחזרה למאמר

לכותבי מאמרים

התחבר הרשמה למערכת שחזור סיסמה

מאמרים בקטגוריות
אימון אישי
אינטרנט והחיים ברשת
בידור ופנאי
ביטוח
בית משפחה וזוגיות
בניין ואחזקה
הודעות לעיתונות
חברה, פוליטיקה ומדינה
חוק ומשפט
חינוך ולימודים
מדעי החברה
מדעי הטבע
מדעי הרוח
מחשבים וטכנולוגיה
מיסים
מתכונים ואוכל
נשים
ספורט וכושר גופני
עבודה וקריירה
עיצוב ואדריכלות
עסקים
פיננסים וכספים
קניות וצרכנות
רוחניות
רפואה ובריאות
תחבורה ורכב
תיירות ונופש

שיווק באינטרנט על ידי WSI